These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34256353)

  • 1. PARP inhibitors in advanced prostate cancer: when to use them?
    Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
    Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
    Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
    Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
    Ziadeh T; Kourie HR
    Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
    Flippot R; Patrikidou A; Aldea M; Colomba E; Lavaud P; Albigès L; Naoun N; Blanchard P; Terlizzi M; Garcia C; Bernard-Tessier A; Fuerea A; Di Palma M; Escudier B; Loriot Y; Baciarello G; Fizazi K
    Drugs; 2022 May; 82(7):719-733. PubMed ID: 35511402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of
    Quigley D; Alumkal JJ; Wyatt AW; Kothari V; Foye A; Lloyd P; Aggarwal R; Kim W; Lu E; Schwartzman J; Beja K; Annala M; Das R; Diolaiti M; Pritchard C; Thomas G; Tomlins S; Knudsen K; Lord CJ; Ryan C; Youngren J; Beer TM; Ashworth A; Small EJ; Feng FY
    Cancer Discov; 2017 Sep; 7(9):999-1005. PubMed ID: 28450426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
    Xia M; Guo Z; Hu Z
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Inhibition in Advanced Prostate Cancer.
    Fenton SE; Chalmers ZR; Hussain M
    Cancer J; 2021 Nov-Dec 01; 27(6):457-464. PubMed ID: 34904808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
    Markowski MC; Sternberg CN; Wang H; Wang T; Linville L; Marshall CH; Sullivan R; King S; Lotan TL; Antonarakis ES
    Oncologist; 2024 Sep; 29(9):794-800. PubMed ID: 38885246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibition in prostate cancer.
    Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
    Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
    Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
    Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
    Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.
    Fan Y; Liu Z; Chen Y; He Z
    Adv Ther; 2024 Jun; 41(6):2196-2216. PubMed ID: 38767824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline Testing in Prostate Cancer: When and Who to Test.
    Sokolova A; Cheng H
    Oncology (Williston Park); 2021 Oct; 35(10):645-653. PubMed ID: 34669358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.